Apimeds Pharmaceuticals US Inc. Issues Correction to Merger Agreement and Certificate of Designation
Reuters
Dec 10, 2025
Apimeds Pharmaceuticals US Inc. Issues Correction to Merger Agreement and Certificate of Designation
Apimeds Pharmaceuticals US Inc. has issued an amendment to its previously filed Form 8-K, correcting clerical errors in the Agreement and Plan of Merger and the Certificate of Designation. The company stated that these corrections were solely to reflect the accurate intent of the parties, with no other material terms or disclosures affected. The corrected documents have been filed as exhibits to the amendment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-119893), on December 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.